The assessment of anti-recurrence efficacy of Prodexin in the treatment of bacterial vaginosis

• Published in: Репродуктивная эндокринология
• Main Authors: D.G. Konkov, V.O. Rud, A.V. Starovier, O.A. Muntyan
• Format: Article
• Language: English
• Published: Publishing House TRILIST 2025-05-01
• Subjects: pro-bavag study; bacterial vaginosis; recurrence; prodexyn; ternidazole; metronidazole; adherence to treatment
• Online Access: https://reproduct-endo.com/article/view/332342
• ISSN: 2309-4117; 2411-1295

Background. Bacterial vaginosis (BV) remains the most common vaginal infection globally, often exhibiting high recurrence rates despite standard antimicrobial therapy. The persistence of BV is frequently attributed to polymicrobial biofilms and altered vaginal microbiota, which challenge conventional treatment efficacy. Objective of the study: To assess the long-term anti-relapse effectiveness and patient adherence associated with Prodexyn (a combination of octenidine dihydrochloride and dexpanthenol) compared to standard topical antimicrobial agents in women with a history of recurrent BV. Materials and methods. In this prospective comparative study (phase II of the PRO-BAVAG project), 119 women with a previous history of BV recurrence were enrolled and stratified based on previous treatment regimens. Participants received either Prodexyn (n = 52), ternidazole (n = 41), or metronidazole (n = 26). Recurrence was evaluated using clinical symptoms and Hay-Ison criteria at 3, 6, and 9 months. Treatment adherence was measured using the MMAS-8 scale. Results. No recurrences were recorded in the Prodexyn group after 3 months. At 6 and 9 months, the recurrence rate remained significantly lower in the Prodexyn group compared to both comparison groups (p < 0.05). Additionally, high adherence to therapy was noted in 92.3% of Prodexyn users, significantly outperforming adherence in the metronidazole and ternidazole groups (p < 0.01). The probable reason for the better anti-relapse effect of Prodexin can be considered the biofilm-targeting effect of octenidine and its lactoflora preserving effect. Conclusions. Prodexyn demonstrated superior long-term efficacy in preventing BV recurrence and showed high patient adherence. Its dual action (targeting vaginal biofilms and preserving lactoflora) suggests a promising alternative to traditional antimicrobial therapies. Further studies are needed to confirm its biofilm-disruptive mechanisms and define optimal treatment durations.